Hepatitis B virus viral load and treatment decision

Authors


  • Potential conflict of interest: Dr. McHutchison is a consultant and received grants from Anadys, Coley Pharmaceutical Group, First Circle Medical, GlaxoSmith- Kline, Human Genome Sciences, Idenix Pharmaceuticals, Intarica, Novartis, Pharmasset, Pfizer, Schering-Plough, Valeant Pharmaceuticals, Vertex Pharmaceuticals, and Wyeth. He received grants from GlobeImmune, Medtronics, Salix Pharmaceuticals, Sanofi-Aventis, Vertex Pharmaceuticals. He is a consultant for Biolex, Epiphany Biosciences, Idera Pharmaceuticals, InterMune Pharmaceuticals, National Genetics Inst., Peregrine, and United Therapeutics. Dr. Tillman advises Gilead Sciences. He owns stock in Abbott and holds intellectual property rights for Evivar. He is also a consultant for, advises, and received grants from Novatis. Dr. Patel advises and is on the speakers' bureau of Gilead Sciences.

No abstract is available for this article.

Ancillary